Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2:374-7.
doi: 10.7150/jca.2.374. Epub 2011 Jul 1.

Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial

Darren R Feldman  1 , Robert Huddart, Emma Hall, Jörg Beyer, Thomas Powles
Affiliations

Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial

Darren R Feldman et al. J Cancer. 2011.

Abstract

Metastatic germ cell tumours (GCTs) are usually cured with cisplatin based chemotherapy and standard treatment algorithms are established. However when this treatment fails and the disease relapses, standard treatment is much more uncertain. Both conventional dose therapy (CDT) and high dose therapy (HDT) are widely used, due to the lack of conclusive data supporting one specific approach. A recent retrospective analysis focusing on this population suggested a significant benefit for HDT. Retrospective analyses are prone to bias, and therefore while this data is provocative it is by no mean conclusive. For this reason the international community is supporting a prospective randomised trial in this area comparing CDT(TIP) with sequential HDT (TICE). The planned open labelled randomised phase III study (TIGER) is due to open in 2011 and will recruit 390 patients to detect a 13% difference in 2 year progression free survival (primary endpoint). It is hoped that this large study will conclusively resolve the uncertainty which currently exists.

Keywords: Metastatic germ cell tumours; dose therapy; relapses.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1
Overview of TIGER study summarizing treatment regimens
See this image and copyright information in PMC

References

    1. Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004; SEER DATABASE 1975-2004. NIH; http://seer.cancer.gov/csr/1975_2004/results_figure/sect_01_zfig.19.pdf.
    1. Lorch A, Kollmannsberger C, Hartmann JT. et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol. 2007 Jul 1;25(19):2778–84. - PubMed
    1. Daugaard G. Management of poor-prognosis or relapsed germ-cell cancer. BJU Int. 2009 Nov;104:1392–7. - PubMed
    1. Connolly RM, McCaffrey JA. High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review. Eur Urol. 2009 Jul;56(1):57–64. - PubMed
    1. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549–55. - PubMed